Enlon

ANDA 88873, held by Pharmobedient. Edrophonium Chloride.

As of Nov 15, 2026, ANDA 88873 (Enlon), held by Pharmobedient, was first approved by FDA on Aug 6, 1985, with 13 approved supplements and 0 published complete response letters.

First approved: Aug 6, 1985
Supplements approved: 13
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 14 submissions below

Date	Submission	Status	Documents
Aug 6, 1985	Original application	Approved	None posted

Products

1 strengths and forms

Product	Active ingredient	Marketing
Enlon10MG/ML · injectable;injection	Edrophonium Chloride	Discontinued

All 14 submissions, including labeling and manufacturing supplements


Jan 10, 2011	Supplement 23Manufacturing	Approved	None posted
Sep 28, 2009	Supplement 22Labeling	Approved	None posted
Apr 3, 2009	Supplement 19Labeling	Approved	None posted
Feb 20, 2001	Supplement 16Manufacturing	Approved	None posted
Feb 20, 2001	Supplement 15Manufacturing	Approved	None posted
Jul 11, 2000	Supplement 14Manufacturing	Approved	None posted
Jul 11, 2000	Supplement 13Manufacturing	Approved	None posted
Nov 22, 1991	Supplement 25Labeling	Approved	None posted
Nov 22, 1991	Supplement 12Labeling	Approved	None posted
Feb 7, 1991	Supplement 10Manufacturing	Approved	None posted
Sep 3, 1987	Supplement 5Manufacturing	Approved	None posted
May 15, 1986	Supplement 2Manufacturing	Approved	None posted
May 15, 1986	Supplement 1Manufacturing	Approved	None posted
Aug 6, 1985	Original application	Approved	None posted

Identifiers

Application: ANDA 88873
Drugs@FDA: Overview at FDA
Company: PharmoBedient

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters